SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

FDA approves RevMed’s Rasonque to slow pancreatic cancer

In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as chemotherapy alone. US regulators approved the drug to slow pancreatic cancer.

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories